Graft Versus Host Disease
205
11
17
107
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
57 trials with published results (28%)
Research Maturity
107 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
21.0%
43 terminated out of 205 trials
71.3%
-15.2% vs benchmark
12%
24 trials in Phase 3/4
53%
57 of 107 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 107 completed trials
Clinical Trials (205)
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
CINC424A2X01B Rollover Protocol
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT
Relationship Between "FODMAPs" and "GVHD"
Optimizing PTCy Dose and Timing
Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease
Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host
Detection of Graft Versus Host Disease With [18F]F-AraG
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients